Initial Beneficial Ownership · 3
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
primary_doc.xml
Filing details
- Report period
- 2026-09-22
- Issuer
- bioAffinity Technologies, Inc.
- Issuer CIK
- 0001712762
- Trading symbol
- BIAF
Reporting owner 1
- Name
- HRT FINANCIAL LP
- Reporting owner CIK
- 0001475597
- Relationship
- 10% owner
- Address
- 3 WORLD TRADE CENTER, 175 GREENWICH STRE, 76TH FLOOR, NEW YORK, NY, 10007
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Stock | 116,782[F1] | D |
Table key
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership |
|---|---|---|---|---|---|---|
| Warrant (rights to buy) | 3,645 | 2022-06-22 | 2027-06-22 | Common Stock | 2.6289[F2] | D |
Table key
- D
- Direct
Footnotes
- F1
- The reporting person became the beneficial owner of more than 10% of the outstanding Common Stock on September 22, 2026. The amount reported represents shares of Common Stock directly held by the reporting person immediately following the transaction that resulted in such status.↩ 1
- F2
- Represents 1,183 warrants held at the time described in footnote (1). Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. The underlying amount is rounded to four decimal places.↩ 1
Signature 1
- Signed
- Adam Nunes
- Date
- 2026-11-19
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.